Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer evolution under the microscope: a major tracking study

NCT ID NCT01888601

Knowledge-focused Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of cancer coming back and improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

814 people

The number who actually took part.

Started

Apr 2014

Expected to finish

Nov 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Stage I-IIIA NSCLC eligible for primary surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written Informed consent * Patients ≥18 years of age, with early stage IIA-IIIB disease (according to TNM 8th edition) who are eligible for primary surgery. Patients with a radiological staging of IB (N0) who could be upstaged to IIA-IIIB following surgery (due to the presence of possible nodal involvement on the pre-operative scan) may also be included, but will be withdrawn if post-surgical staging remains IB. Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g. diagnosis determined from frozen section in theatre) * Primary surgery in keeping with NICE guidelines planned (see section 9.3) * Agreement to be followed up at a TRACERx site * Performance status 0 or 1 * Minimum tumour diameter at least 15mm to allow for sampling of at least two tumour regions (if 15mm, a high likelihood of nodal involvement on pre-operative imaging required to meet eligibility according to stage, i.e. T1N1-3) Exclusion Criteria: * Any other\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy). * Any other\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\*\*. \*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer \*\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC. * Psychological condition that would preclude informed consent * Treatment with neo-adjuvant therapy for current lung malignancy deemed necessary * Post-surgery staging is not IIA-IIIB * Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection. * Sufficient tissue, i.e. a minimum of two tumour regions, is unlikely to be obtained for the study based on pre-operative imaging

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Ashford and St Peter's Hospitals NHS Foundation Trust

    Chertsey, Surrey, KT16 0PZ, United Kingdom

  • Barts Health NHS Trust

    London, E1 1RD, United Kingdom

  • Cardiff and Vale University Health Board

    Cardiff, CF14 4XW, United Kingdom

  • Grampian Health Board

    Aberdeen, AB15 6RE, United Kingdom

  • Heart of England NHS Foundation Trust

    Birmingham, B9 5SS, United Kingdom

  • Liverpool Heart and Chest Hospital

    Liverpool, United Kingdom

  • NHS Greater Glasgow & Clyde

    Glasgow, United Kingdom

  • North Middlesex University Hospital NHS Trust

    London, N18 1QX, United Kingdom

  • Royal Brompton & Harefield NHS Foundation Trust

    London, SW3 6NP, United Kingdom

  • Royal Free Hospital

    London, NW3 2QG, United Kingdom

  • Royal Free London NHS Foundation Trust - Barnet Hospital

    London, NW3 2QG, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, S5 7AU, United Kingdom

  • The Princess Alexandra Hospital NHS Trust

    Harlow, Essex, CM20 1QX, United Kingdom

  • The Whittington Hospital NHS Trust, trading as Whittington Health

    London, N19 5NF, United Kingdom

  • University College London Hospitals NHS Foundation Trust

    London, Select Region, NW1 2PG, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • University Hospital of South Manchester NHS Foundation Trust

    Manchester, M23 9LT, United Kingdom

  • University Hospitals of Leicester NHS Trust

    Leicester, LE1 5WW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.